OMERS ADMINISTRATION Corp Acquires New Shares in Guardant Health, Inc. (NASDAQ:GH)

OMERS ADMINISTRATION Corp bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 20,800 shares of the company's stock, valued at approximately $635,000.

A number of other institutional investors also recently modified their holdings of the company. Norges Bank bought a new stake in Guardant Health in the 4th quarter worth approximately $36,438,000. Deep Track Capital LP lifted its stake in shares of Guardant Health by 7.0% during the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock valued at $196,118,000 after buying an additional 419,006 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Guardant Health by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after buying an additional 350,606 shares in the last quarter. Eversept Partners LP purchased a new stake in Guardant Health in the 4th quarter worth $8,433,000. Finally, Blue Water Life Science Advisors LP lifted its stake in Guardant Health by 53.9% in the 4th quarter. Blue Water Life Science Advisors LP now owns 694,047 shares of the company's stock worth $21,203,000 after purchasing an additional 243,000 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the sale, the chief executive officer now owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. The trade was a 4.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 107,132 shares of company stock worth $5,248,393. 6.10% of the stock is owned by insiders.

Guardant Health Stock Performance

NASDAQ GH traded up $0.95 during trading on Friday, reaching $38.00. The company's stock had a trading volume of 1,373,039 shares, compared to its average volume of 2,145,131. The firm has a market cap of $4.71 billion, a price-to-earnings ratio of -10.67 and a beta of 1.49. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $52.92. The business's fifty day moving average price is $43.39 and its 200-day moving average price is $40.16.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same period in the prior year, the business posted ($0.46) earnings per share. The firm's revenue for the quarter was up 20.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GH has been the topic of several analyst reports. Stephens reiterated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. Scotiabank restated an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. Stifel Nicolaus upped their target price on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Mizuho started coverage on shares of Guardant Health in a research note on Thursday, April 10th. They issued an "outperform" rating and a $55.00 target price on the stock. Finally, Canaccord Genuity Group upped their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Guardant Health currently has a consensus rating of "Buy" and a consensus price target of $52.32.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.